Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials

Purpose To investigate the role of baseline demographics, disease characteristics, and treatment responses to ranibizumab during RIDE/RISE in predicting long-term treatment frequency with a criteria-based pro re nata (PRN) regimen during the open-label extension (OLE). Design Pooled, retrospective,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Ophthalmology (Rochester, Minn.) Minn.), 2016-08, Vol.123 (8), p.1716-1721
Hauptverfasser:	Wykoff, Charles C., MD, PhD, Elman, Michael J., MD, Regillo, Carl D., MD, Ding, Beiying, PhD, Lu, Na, PhD, Stoilov, Ivaylo, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angiogenesis Inhibitors - administration & dosage Blood Glucose - metabolism Diabetic Retinopathy - diagnosis Diabetic Retinopathy - drug therapy Female Glycated Hemoglobin A - metabolism Humans Intravitreal Injections Macular Edema - diagnosis Macular Edema - drug therapy Male Middle Aged Ophthalmology Ranibizumab - administration & dosage Retrospective Studies Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!